SGCB and pulmonary hypertension: Recently, sGC has proven to be a key enzyme in the treatment of various cardiovascular pathologies since sGC stimulators and activators are in preclinical and clinical development for the treatment of pulmonary hypertension, which has been reported as a new and promising milestone in the field of NO/sGC/cGMP pharmacology [9].